Effects of the selective α 1a-adrenoceptor antagonist silodosin on ECGs of healthy men in a randomized, double-blind, placebo-and moxifloxacin-controlled study

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 5, 2010, Pages 609-613

  Morganroth, J ^a   Lepor, H ^b   Hill, L A ^c   Volinn, W ^c   Hoel, G ^c  

^a eResearchTechnology   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Watson Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN; PLACEBO; SILODOSIN;

ADULT; ANALYSIS OF COVARIANCE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ELECTROCARDIOGRAM; FATIGUE; HEADACHE; HEART PALPITATION; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PULSE RATE; QRS COMPLEX; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RETROGRADE EJACULATION; SOMNOLENCE; TREATMENT DURATION;

ADOLESCENT; ADULT; AZA COMPOUNDS; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; HEART RATE; HUMANS; INDOLES; LONG QT SYNDROME; MALE; MIDDLE AGED; QUINOLINES; RECEPTORS, ADRENERGIC, ALPHA-1; YOUNG ADULT;

EID: 77951498815     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.265     Document Type: Article

References (17)

1. Gupta, a., Lawrence, a.T., Krishnan, K., Kavinsky, C.J. & Trohman, R.G. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am. Heart J. 153, 891-899 (2007).
2. arizona Center for Education and Research on Therapeutics (aZCERT). Overview of Long QT Syndrome and Torsades http://www.azcert.org/medical-pros/ education/practical-approach.cfm. accessed 19 September 2008
3. ICH E14. Guidance for Industry: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs. October 2005. Issued by the US Department of Health and Human Services, Food and Drug administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. approved by the International Conference on Harmonisation http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ ucm129357.pdf.
4. Marks, L.S., Gittelman, M.C., Hill, L.a., Volinn, W. & Hoel, G. Rapid efcacy of the highly selective α1a-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J. Urol. 181, 2634-2640 (2009).
5. yamada, S., Okura, T. & Kimura, R. In vivo demonstration of α1a-adrenoceptor subtype selectivity of KMD-3213 in rat tissues. J. Pharmacol. Exp. Ther. 296, 160-167 (2001).
6. Murata, S., Taniguchi, T., Takahashi, M., Okada, K., akiyama, K. & Muramatsu, I. Tissue selectivity of KMD-3213, an α1-adrenoreceptor antagonist, in human prostate and vasculature. J. Urol. 164, 578-583 (2000).
7. Shibata, K. et al. KMD-3213, a novel, potent, α1a-adrenoceptor- selective antagonist: characterization using recombinant human α1-adrenoceptors and native tissues. Mol. Pharmacol. 48, 250-258 (1995).
8. Lepor, H., Lepor, N.E., Hill, L.a. & Trohman, R.G. The QT interval and selection of α-blockers for benign prostatic hyperplasia. Rev. Urol. 10, 85-91 (2008).
9. Lacerda, a.E. et al. alfuzosin delays cardiac repolarization by a novel mechanism. J. Pharmacol. Exp. Ther. 324, 427-433. 2008,
10. Tatemichi, S., Kiguchi, S., Kobayashi, M., yamazaki, y., Shibata, N. & Uruno, T. Cardiovascular efects of the selective α1a-adrenoceptor antagonist silodosin (KMD-3213), a drug for the treatment of voiding dysfunction. Arzneimittelforschung. 56, 682-687 (2006).
11. yamada, S., Kato, y., Okura, T., Kagawa, y. & Kawabe, K. Prediction of α1-adrenoceptor occupancy in the human prostate from plasma concentrations of silodosin, tamsulosin and terazosin to treat urinary obstruction in benign prostatic hyperplasia. Biol. Pharm. Bull. 30, 1237-1241 (2007).
12. Bloomfeld, D.M. et al. The efect of moxifoxacin on QTc and implications for the design of thorough QT studies. Clin. Pharmacol. Ther. 84, 475-480 (2008).
13. Stylianou, a., Roger, J. & Stephens, K. a statistical assessment of QT data following placebo and moxifoxacin dosing in thorough QT studies. J. Biopharm. Stat. 18, 502-516 (2008).
14. Sherazi, S., DiSalle, M., Daubert, J.P. & Shah, a.H. Moxifoxacin-induced torsades de pointes. Cardiol. J. 15, 71-73 (2008).
15. Uroxatral Prescribing Information (alfuzosin HCl Extended-Release Tablets) http://products.sanof-aventis.us/uroxatral/uroxatral.html. accessed 8 December 2008
16. Schwinn, D.a. & Roehrborn, C.G. α1-adrenoceptor subtypes and lower urinary tract symptoms. Int. J. Urol. 15, 193-199 (2008).
17. Malik, M., Färbom, P., Batchvarov, V., Hnatkova, K. & Camm, a.J. Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval. Heart. 87, 220-228 (2002).